Skip to main content Help with accessibility Skip to main navigation

Risankizumab

Indication

Treating active psoriatic arthritis after inadequate response to DMARDs - NICE TA803

NICE TA803 - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs

Red

Brand:

Nice TA:

803

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Musculoskeletal system

Background

1.1 Risankizumab, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have:

  • peripheral arthritis with 3 or more tender joints and 3 or more swollen joints

  • moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index [PASI] score greater than 10)

  • had 2 conventional DMARDs and at least 1 biological DMARD.

    Risankizumab is recommended only if the company provides it according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 14 - Sep - 2022